Sofituzumab vedotin维汀-索非妥珠单抗维汀

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sofituzumab vedotin

CAS No. : 1418200-58-4

MCE 国际站：Sofituzumab vedotin

产品活性：Sofituzumab vedotin (DMUC5754A) 是一种含有 MMAE 的抗 MUC16 抗体-药物偶联物 (ADC)，具有蛋白酶切割连接子。Sofituzumab vedotin 可用于癌症研究。

研究领域：Antibody-drug Conjugate/ADC Related

作用靶点：Antibody-Drug Conjugates (ADCs)

In Vitro: Sofituzumab vedotin (DMUC5754A) is an antibody–drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl.
Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16TMlong cells proliferation in a dose-dependent manner.

In Vivo: Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models.

相关产品：Trastuzumab deruxtecan  |  Trastuzumab emtansine  |  Sacituzumab govitecan  |  Disitamab vedotin  |  Brentuximab vedotin  |  Enfortumab vedotin-ejfv  |  Gemtuzumab ozogamicin  |  Datopotamab deruxtecan  |  Mirvetuximab soravtansine  |  Telisotuzumab vedotin  |  Patritumab deruxtecan  |  Belantamab mafodotin  |  Labetuzumab govitecan  |  Tusamitamab ravtansine  |  Loncastuximab tesirine  |  Polatuzumab vedotin  |  Tisotumab vedotin  |  Farletuzumab ecteribulin  |  Glembatumumab vedotin  |  Cantuzumab mertansine  |  Cantuzumab ravtansine  |  Depatuxizumab MMAE  |  Exatecan Intermediate 3  |  Izeltabart  |  KRAS degrader-1  |  Moxetumomab pasudotox  |  SMP-33693

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds